{
    "nct_id": "NCT04196283",
    "official_title": "A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
    "inclusion_criteria": "* Participants should weigh at least 35 kg.\n* Eastern Cooperative Oncology Group performance status of 0 or 1 and a life expectancy of >= 3 months.\n* Participant have >= 1 lesion accessible for intratumoral injection.\n* Histologically or cytologically confirmed R/M HNSCC (of the following 4 subsites: oral cavity, oropharynx, larynx, and hypopharynx) who previously progressed either during or after <= 3 prior treatment regimens administered in the recurrent or metastatic setting.\n\n  * Must have received 1 immunotherapy regimen which included a PD-(L)1 inhibitor.\n  * Must have received platinum-based therapy, or be considered ineligible for platinum-based therapy by the investigator.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Uncontrolled metastases to the central nervous system (CNS).\n\n  * Participants with brain metastases are eligible provided that evidence of clinical and radiographic stable disease for at least 4 weeks after definitive therapy is given and participants have not used prohibited levels of steroids for at least 4 weeks prior to first dose of the study.\n* Received prior treatment with OX40 or toll-like receptor (TLR) agonists (excluding topical agents).",
    "miscellaneous_criteria": ""
}